Xenetic Biosciences (XBIO)
(Delayed Data from NSDQ)
$4.00 USD
-0.05 (-1.30%)
Updated Jun 4, 2024 03:59 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XBIO 4.00 -0.05(-1.30%)
Will XBIO be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for XBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XBIO
Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
XBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates
Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
Other News for XBIO
Xenetic Biosciences appoints James Parslow as interim CEO
Xenetic names James Parslow as interim CEO
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
Xenetic Biosciences reports Q1 results
Xenetic reports Q1 EPS (78c) vs. (56c) last year